Navigation Links
Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
Date:8/8/2012

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of Andrew J. McKnight, Ph.D. as Senior Director, Target Biology.  Dr. McKnight comes to AnaptysBio with extensive experience in the design and development of novel therapeutic antibodies across a variety of therapeutic areas.  Working together with David J. King, Ph.D., AnaptysBio's chief scientific officer, Dr. McKnight will be leading the advancement of AnaptysBio's current and future internal pipeline programs. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

AnaptysBio's primary objective is the advancement of novel therapeutic antibody programs generated using the Company's proprietary SHM-XEL platform.  As the first company to replicate somatic hypermutation (SHM) in vitro for antibody discovery, AnaptysBio's SHM-XEL platform is uniquely positioned to generate therapeutic antibodies with unique functionality.  The Company is currently pursuing differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's internal programs are independent of the Company's partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA. 

Dr. McKnight comes to AnaptysBio most recently from Pfizer's Biotherapeutics group, where he directed numerous internal and partnered antibody development projects.  Prior to Pfizer, Dr. McKnight led antibody projects at UCB-Celltech. Dr. McKnight received his doctorate from University of Oxford and was a postdoctoral fellow at Harvard Medical School. 

"We are delighted to add Andrew's target biology experience to AnaptysBio's research and development team," said Hamza Suria, AnaptysBio's president and chief executive officer. "The unique strengths of our SHM-XEL platform provide AnaptysBio with distinct advantages in the design and discovery of novel therapeutic antibodies."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies.  AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.   AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene and Gilead.  Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit www.anaptysbio.com.


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asthmapolis Expands Dignity Health Study to Include Mercy Medical Group Patients
2. Hospira Expands Board of Directors With Election of Dennis M. Fenton
3. The MED Group Expands MED Suppliers Network to add Ventilator Program
4. Integrity Life Sciences Expands Orthotic Options for Domestic and International Customers
5. Practice Fusion Expands Executive Team with Addition of General Counsel and Associate VP of Corporate Development
6. OceanGate Inc. Expands Board of Directors with Two Key Appointments
7. ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
8. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
9. Echo Therapeutics Expands License Agreement with Ferndale Pharma
10. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
11. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2019)... ... December 05, 2019 , ... Cognosante is ... Sector Partner Program; a designation that will accelerate digital transformation for public ... partners that offer solutions and proven experience delivering on government, education and ...
(Date:12/5/2019)... ... December 05, 2019 , ... Intelligent.com, a trusted resource ... Respiratory Therapy Degree Programs for 2020. The comprehensive research guide is based on ... is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. ...
(Date:12/5/2019)... ... 2019 , ... LeadingBiotech ,?an exclusive event series bringing ... to be discussed at its East/West CEO conference to be held ... , Kicking off the week of the J.P. Morgan Healthcare Conference ...
Breaking Medicine Technology:
(Date:12/5/2019)... ... 05, 2019 , ... A cohort of plastic surgeons across ... their patients more easily detect ruptured silicone gel implants. Dr. Herluf Lund, a ... on his experience. While the FDA currently recommends regular MRI scans for women ...
(Date:12/5/2019)... ... ... Abide, the #1 Christian meditation and sleep app, has helped adults and ... Listeners have recovered from bad dreams and night terrors, quit using sleeping pills, and ... of Americans suffer from poor sleep, which is linked to diabetes, obesity and depression. ...
(Date:12/5/2019)... ... December 05, 2019 , ... HealthCareMandA.com is hosting an interesting ... on Thursday, December 12, 2019, at 1:00 PM ET. , Private equity firms ... firms are scrambling to assemble regional platforms with enough scale and talent to ...
(Date:12/5/2019)... , ... December 05, 2019 , ... ... planning, has announced the Top 54 RHIT Degree Programs for 2020. The comprehensive ... in the nation. Each program is evaluated based on curriculum quality, graduation rate, ...
(Date:12/5/2019)... ... December 05, 2019 , ... It’s been ... exceptional products that help people embrace, achieve, and maintain a healthy lifestyle to ... more committed to our mission of impacting world health, so it’s gratifying to ...
Breaking Medicine News(10 mins):